• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India.药物不良反应的特征及影响因素:对印度国家结核病防治项目下接受治疗的结核病患者的一项分析研究
F1000Res. 2024 Jul 23;11:1388. doi: 10.12688/f1000research.125815.2. eCollection 2022.
2
Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.印度耐药结核病规划管理中利奈唑胺的药物不良反应:一项回顾性多中心研究。
Indian J Tuberc. 2024;71 Suppl 1:S101-S109. doi: 10.1016/j.ijtb.2023.04.006. Epub 2023 Apr 10.
3
Adverse Drug Reaction Patterns of First-line Anti-tubercular Drugs among Saharia Tuberculosis Patients: An Observational Study in Particularly Vulnerable Tribal Group of Madhya Pradesh, India.印度中央邦特别脆弱部落群体的撒哈拉结核病患者一线抗结核药物不良反应模式:一项观察性研究。
Indian J Public Health. 2023 Oct 1;67(4):542-545. doi: 10.4103/ijph.ijph_865_22. Epub 2023 Dec 29.
4
Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study.印度直接观察治疗策略下糖尿病对结核病治疗结局和不良反应的影响:一项前瞻性研究。
Biomed Res Int. 2016;2016:7273935. doi: 10.1155/2016/7273935. Epub 2016 Aug 24.
5
Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.印度德里一家三级医疗中心耐药结核病的流行病学及行为学关联
Indian J Tuberc. 2019 Jul;66(3):331-336. doi: 10.1016/j.ijtb.2018.06.003. Epub 2018 Jul 10.
6
Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.印度西部古吉拉特邦耐多药结核病方案停药的不良反应和危险因素。
Natl Med J India. 2020 Jan-Feb;33(1):10-14. doi: 10.4103/0970-258X.308234.
7
'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.“在修订后的国家结核病控制规划下,我们是否漏报了药物不良反应?”——印度班加罗尔的一项混合方法研究。
Indian J Tuberc. 2020 Jan;67(1):20-28. doi: 10.1016/j.ijtb.2020.01.003. Epub 2020 Jan 15.
8
Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.NAT2、GSTM1、GSTT1、CYP2E1 基因与环境因素的遗传相互作用与抗结核药物不良反应有关。
Mol Diagn Ther. 2012 Aug 1;16(4):241-50. doi: 10.1007/BF03262213.
9
Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India.印度西部半城市和农村地区药物敏感肺结核患者的费用。
Infect Dis Poverty. 2020 Oct 19;9(1):144. doi: 10.1186/s40249-020-00760-w.
10
The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients.耐多药肺结核患者的药物不良反应严重程度与治疗时间的长短呈正相关。
Indian J Tuberc. 2024;71 Suppl 1:S97-S100. doi: 10.1016/j.ijtb.2024.06.001. Epub 2024 Jun 10.

引用本文的文献

1
Anti-tuberculosis drug-induced hepatotoxicity and associated risk factors among patients with pulmonary tuberculosis at a tertiary care hospital in Thailand.泰国一家三级护理医院肺结核患者中抗结核药物引起的肝毒性及相关危险因素
IJID Reg. 2025 May 8;15:100665. doi: 10.1016/j.ijregi.2025.100665. eCollection 2025 Jun.

本文引用的文献

1
Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.印度耐药结核病规划管理中利奈唑胺的药物不良反应:一项回顾性多中心研究。
Indian J Tuberc. 2024;71 Suppl 1:S101-S109. doi: 10.1016/j.ijtb.2023.04.006. Epub 2023 Apr 10.
2
Adverse effects and duration of treatment of TB in Canterbury, New Zealand.新西兰坎特伯雷地区结核病的不良反应及治疗持续时间。
Int J Tuberc Lung Dis. 2021 Dec 1;25(12):990-994. doi: 10.5588/ijtld.21.0345.
3
Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy.在治愈与折磨之间:耐多药结核病治疗中的不良反应负担
Patient Prefer Adherence. 2021 Nov 23;15:2597-2607. doi: 10.2147/PPA.S333111. eCollection 2021.
4
Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.印度西部古吉拉特邦耐多药结核病方案停药的不良反应和危险因素。
Natl Med J India. 2020 Jan-Feb;33(1):10-14. doi: 10.4103/0970-258X.308234.
5
"Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.“副作用——治疗方案的一部分”:在印度古吉拉特邦,采用混合方法研究程序化治疗耐多药肺结核(DR-TB)患者的不良事件。
BMC Infect Dis. 2020 Dec 2;20(1):918. doi: 10.1186/s12879-020-05660-w.
6
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.药物相关不良事件在耐多药结核病治疗中的作用:一项个体患者数据荟萃分析。
Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.
7
Adverse drug reactions in tuberculosis and management.结核病中的药物不良反应及管理
Indian J Tuberc. 2019 Oct;66(4):520-532. doi: 10.1016/j.ijtb.2019.11.005.
8
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.耐药结核病治疗中不良反应监测:第一份全球报告。
Eur Respir J. 2019 Dec 19;54(6). doi: 10.1183/13993003.01522-2019. Print 2019 Dec.
9
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.抗结核治疗的依从性干预措施及结局:试验和观察性研究的系统评价和荟萃分析。
PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.
10
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.执行摘要:美国胸科学会/疾病控制与预防中心/美国传染病学会官方临床实践指南:药物敏感型结核病的治疗
Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

药物不良反应的特征及影响因素:对印度国家结核病防治项目下接受治疗的结核病患者的一项分析研究

Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India.

作者信息

Shah Harsh, Yasobant Sandul, Patel Jay, Bhavsar Priya, Saha Somen, Patel Yogesh, Saxena Deepak, Sinha Anish

机构信息

Department of Public Health Science, Indian Institute of Public Health, Gandhinagar, Gandhinagar, Gujarat, 382042, India.

School of Epidemiology and Public Health, Datta Meghe Institute of Medical Sciences, Wardha, Sawangi (Meghe), Wardha, Maharashtra, 442004, India.

出版信息

F1000Res. 2024 Jul 23;11:1388. doi: 10.12688/f1000research.125815.2. eCollection 2022.

DOI:10.12688/f1000research.125815.2
PMID:39935535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11811607/
Abstract

Background Tuberculosis (TB) continues to pose a serious threat to the public health system in India. Although the National Tuberculosis Elimination Program (NTEP) is providing a wide range of interventions from early diagnosis to complete treatment to reduce morbidity and mortality from TB, adverse drug reactions (ADR) remain a challenge in treatment adherence and completion. Methods An observational cross-sectional study was conducted in selected districts of Gujarat state. A total of 593 reported TB patients were recruited with an adjusted unified distribution based on the type of cases, site of diseases, and service facility through a simple random sampling method. A semi-structured questionnaire tool was used to collect socio-demographic, clinical, and ADR-related data from the TB patients. Data was analyzed for the frequency, percentage, chi-squared, and adjusted odds ratio to find the association between the variables. Results The majority of the study participants were male (87.2%), aged 15 to 60 (57.8%), daily laborers (22.4%), and married (64.2%). Over 75% of individuals had pulmonary TB, with 87% having experienced their first episode, 83% being new cases, and 44.7% having a history of addiction. ADR with mild symptoms was reported by more than a quarter (29%) of TB patients during the intensive phase (77%). The association between ADR experience and drug susceptibility was significant (p<0.005) and drug-resistant TB patients experience two times more ADRs than drug-sensitive TB patients (OR 2.04). Binomial logistic regression was carried out to describe the association between various variables and occurrence of ADRs. Conclusion The study highlighted a need to enhance health care providers' capacity and program structure for managing ADRs among TB patients. In order to completely eliminate TB across the country, it also emphasized the attention for a holistic and all-encompassing strategy for managing TB patients at the field level.

摘要

背景

结核病(TB)继续对印度的公共卫生系统构成严重威胁。尽管国家结核病消除计划(NTEP)正在提供从早期诊断到完整治疗的广泛干预措施,以降低结核病的发病率和死亡率,但药物不良反应(ADR)仍然是治疗依从性和完成治疗方面的一个挑战。方法:在古吉拉特邦的选定地区进行了一项观察性横断面研究。通过简单随机抽样方法,根据病例类型、疾病部位和服务设施,对593名报告的结核病患者进行了调整后的统一分布招募。使用半结构化问卷工具从结核病患者中收集社会人口统计学、临床和ADR相关数据。对数据进行频率、百分比、卡方和调整后的优势比分析,以找出变量之间的关联。结果:大多数研究参与者为男性(87.2%),年龄在15至60岁之间(57.8%),为日工(22.4%),已婚(64.2%)。超过75%的个体患有肺结核,其中87%经历过首次发作,83%为新病例,44.7%有成瘾史。在强化期(77%),超过四分之一(29%)的结核病患者报告有轻度症状的ADR。ADR经历与药物敏感性之间的关联显著(p<0.005),耐药结核病患者经历的ADR是药物敏感结核病患者的两倍(OR 2.04)。进行了二项逻辑回归以描述各种变量与ADR发生之间的关联。结论:该研究强调需要提高医疗保健提供者管理结核病患者ADR的能力和项目结构。为了在全国范围内彻底消除结核病,它还强调了在现场层面管理结核病患者的整体和全面战略的重要性。